Kornimate/medical-research-clean huggingface dataset:
making connections thru music

Conditions: Dementia; Alzheimer Disease; Vascular Dementia

Summary: healthcare systems around the world, including within the united states, have long-established shortages of trained caregivers. the american health care association states that "the health care system has experienced a shortage of trained caregivers for critical roles for some time." this scarcity directly impacts the 45,800 long-term care (ltc) communities throughout the u.s. concurrent with this staff shortage, more than half of ltc residents have some form of dementia. these two issues create a serious public health concern, since dementia is associated with a variety of behavioral expressions, such as aggression, anxiety, and agitation. behavioral expressions of dementia can be successfully managed with the use of tailored, psychosocial interventions and communication support. unfortunately, existing staff shortages make the facilitation of such interventions challenging. one powerful and often-overlooked approach to ameliorating staffing shortages involves the utilization of retired volunteers to facilitate interventions for persons with dementia (pwd). based on the nearly universal love of music and a promising pilot study, the product to be developed and tested in this sttr will build upon the combined prior work of the principal investigators. making connections thru music (mctm), an urgently needed product, will enable retired volunteers to facilitate an evidence-based music and discussion intervention with pwd. mctm aims to improve engagement, enhance quality of life, and reduce behavioral expressions in pwd. the intervention will consist of two main components: (1) a comprehensive online training course for volunteers, which will provide a general overview of dementia, demonstrate effective communication strategies to use with pwd, and instruct volunteers to effectively facilitate mctm sessions, and (2) an app containing a structured mctm intervention protocol and toolkit, which will be the means by which volunteers facilitate mctm. mctm will be marketed to ltc communities.


Eligibility criteria:
inclusion criteria: * volunteers must be aged 55+ and speak/read conversational english. * staff participants must be at least 18 years old, work within a residential care facility participating in the study, and speak and read english. exclusion criteria: * volunteers will be excluded if they are diagnosed with dementia based on self-report and/or if they score 23 or lower on themini mental state exam (mmse; folstein et al., 1975). such a score would be indicative of possible cognitive impairment. * staff members will be excluded if they work third shift only. pwd residents with dementia must be diagnosed with dementia (any type), score 10 or above on the mmse, be aged 65+, and speak/read conversational english. * pwd will be excluded if they show signs of rapid physical or cognitive decline (based upon staff report or as evidenced by information gained during screening).
long-term follow-up study of al-001 ophthalmic injection in subjects with wamd

Conditions: Wet Age-related Macular Degeneration (wAMD)

Summary: this study is designed to evaluate long-term safety and efficacy of al-001 ophthalmic injection following suprachoroidal space(scs) administration in subjects with wamd. eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of al-001 administered via suprachoroidal space injection.


Eligibility criteria:
inclusion criteria: * the subjects enrolled in al-001 study and received al-001 ophthalmic injection. * the subject or their legal representative agrees to participate in this study and signs a written icf. * the subjects are willing and able to follow planned visits and procedures. exclusion criteria: * none
survival and prognostic factors of squamous cell carcinoma of the nasal vestibule

Conditions: Nasal Vestibule Carcinoma; Rhinectomy; Nasal Vestibule; Squamous Cell Carcinoma

Summary: the goal of this observational study is to learn about survival and prognostic factors in patients who underwent surgical treatment for primary squamous cell carcinoma of the nasal vestibule. the main questions it aims to answer are: * what is the prognosis of patients affected by squamous cell carcinoma of the nasal vestibule? * are there any specific factors that could influence prognosis? * is it possible to elaborate a new staging system, able to overcome the limitations of the currently used ones? data about patients, tumour and type of surgery performed will be collected. participants will be followed-up for a minimum 6 months period after surgery.

this study will address the survival of patients with squamous cell carcinoma of the nasal vestibule (nv-scc), and it will analyze factors influencing it. in particular, apart from demographic features of the patient, data regarding the origin of the tumour and its extension will be collected and the lesion will be restaged according the the three classification systems used at present (wang's classification, ajcc for nasal cavity cancers, ajcc for non-melanomatous skin cancer of head and neck region), given the current controversy regarding the best staging system. furthermore data related to the surgery and the final histology will be collected. all collected data will be analyzed in order to investigate any possible factor related to overall survival, disease specific survival and disease free survival. patients will be followed for a minimum of 6 months up to 5 years after surgery.

Eligibility criteria:
inclusion criteria: * diagnosis of squamous cell carcinoma of the nasal vestibule * underwent upfront surgical treatment with curative intent * availability of clinical and radiological data for ct reassessment * availability of histological samples for pt reassessment * follow-up of at least 6 months after surgery. exclusion criteria: * patients initially referred for disease persistence or recurrence * patients affected by tumour involving the nasal vestibule but originating from other sites (eg. nasal cavities, skin of the nasal pyramid or upper lip)

Keywords: nasal vestibule squamous cell carcinoma rhinectomy
accurate point of care liver disease diagnostics

Conditions: NAFLD; Nonalcoholic Fatty Liver

Summary: this research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. the investigators are testing a new technology to evaluate the liver (liverscope®), and they will compare it to other methods to evaluate the liver, including advanced conventional liver mr and liver fibroscan® ultrasound exams. mr exams and fibroscan® ultrasound exams are common exams used to monitor nafld. conventional mr scanners use magnetic fields and radio waves to make pictures of the liver. liverscope® is a small, portable mr-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. liverscope® currently is not approved for clinical use. in this study the investigators will learn how liverscope® measurements of the liver compare to mr. study participants will be asked to complete a one-time visit which includes: * liverscope exam * mr exam * fibroscan exam (optional) * blood draw * completion of study questionnaires


Eligibility criteria:
inclusion criteria: * age:18 years or older * known or clinically suspected nafld * weight less than 350 lbs (safety limit of mr scanner table) * able to lie on liverscope® diagnostic table for about 15 min * able to hold breath repeatedly for about 20 s during mr and liverscope® exams * willing and able to undergo all study procedures exclusion criteria: * va patient only; not a ucsd patient * ucsd or livivos study personnel * mr contraindication(s) * potential participant states that she knows that she is pregnant, thinks she may be pregnant or states she is trying to become pregnant\* * known chronic liver disease other than nafld
effectiveness of bnt162b2 formulations using state vaccine registry and insurance claims data

Conditions: SARS-CoV-2; COVID-19 Vaccines

Summary: the primary purpose of this study is to learn about how well different versions of the pfizer-biontech covid-19 vaccine (called bnt162b2) work at preventing death, severe covid-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. pfizer is not enrolling any participants for this study. instead, existing data from different health data sources will be used to help answer the scientific questions pfizer is interested in learning more about.


Eligibility criteria:
inclusion criteria: * people with at least one year of pharmacy and medical enrollment in healthverity prior to vaccine availability * state of california or louisiana resident for at least one year exclusion criteria: * people currently pregnant, * individuals with discrepancies in sex and/or year of birth between healthverity claims and california/louisiana immunization registry datasets * a diagnosis of covid-19 in any setting ≤ 90 days prior to start of study or receipt covid-19 vaccine ≤ 90 days prior to start of study.

Keywords: covid-19 xbb vaccine effectiveness
the efficacy and safety of venostan in promoting postoperative swelling reduction in patients with ankle fractures

Conditions: Swelling/ Edema

Summary: this study is a multicenter, open-label, randomized controlled trial planned to enroll patients with ankle fractures who meet the inclusion and exclusion criteria and are scheduled to undergo internal fixation surgery from the emergency and inpatient wards of multiple hospitals. general and disease-related data will be collected. all eligible patients must voluntarily sign an informed consent form after understanding and accepting the study. successfully recruited participants will undergo internal fixation surgery at a scheduled time and then be randomly assigned to either the venostan (horse chestnut seed extract tablet) group or the conventional treatment group. they will receive the corresponding treatments according to the study protocol. follow-up assessments will include changes in ankle circumference, ankle range of motion, scale evaluation results, laboratory test results, and adverse events. the study aims to evaluate the effects of venostasin in patients with ankle fractures undergoing internal fixation surgery, exploring its potential to promote postoperative reduction of ankle swelling, enhance early joint function recovery, and investigate its safety in postoperative fracture management.


Eligibility criteria:
inclusion criteria: * ≥18 year old, no gender restriction; * diagnosed with ankle fracture confirmed by imaging data, ao classification: ---ao-43, ao-44-f3, ao-44; * scheduled to undergo open reduction and internal fixation surgery; * voluntary signing of the informed consent form. exclusion criteria: * pregnant or lactating women; * with contraindications to surgery; * with other severe combined injuries or soft tissue infections; * severe multiple trauma: injury severity score (iss) \> 16; * with concurrent fractures of the spine, pelvis, or ipsilateral or contralateral lower limbs; * pathological fractures; * with peripheral vascular disease or deep vein thrombosis (dvt); * with severe impairment of heart, lung, liver, or kidney function or abnormal coagulation function; * unable to walk independently before the injury; * with pre-existing lower limb edema (e.g., due to liver cirrhosis, kidney disease, etc.) before the injury; * with mental disorders or hyperalgesia; * allergic to any component of the investigational drug; * any contraindications that limit clinical evaluation and treatment of the patient; * deemed unsuitable for inclusion in this study by the investigator.

Keywords: ankle fracture edema postoperative rehabilitation horse chestnut seed extract venostan enhanced recovery after surgery
biomechanics based prediction of preterm delivery

Conditions: Preterm Delivery

Summary: quantitative information on the biomechanical properties of the ecto-cervix in mid-pregnancy will be compared between women with term vs. preterm delivery. we aim to demonstrate that biomechanical data (asp and cci) might complement morphological data (cl) to improve prediction of preterm delivery. it is expected that women with preterm delivery will show stronger weakening of cervical tissue. aspiration (asp) and cervical cci (cervical consistency index) measurements are performed at mid-pregnancy: detection at this time point is useful for therapy and biomechanical modifications are already significant so to enable differentiation by biomechanical measurements (asp and cci).


Eligibility criteria:
inclusion criteria: * all pregnant women presenting at their mid pregnancy consultation (18+0 - 22+0 weeks of pregnancy) are eligible * signed informed consent after being informed is a prerequisite for enrollment. exclusion criteria: * communication problems * missing consent * age\<18 * active bleeding / premature rupture of membranes (prom) * active genital infection * known carrier of hiv or hepatitis b or c * placenta praevia * müllerian anomalies * known or suspected non-compliance, drug or alcohol abuse * cerclage * use of pessary

Keywords: preterm delivery diagnostics biomechanics
desoximetasone spray 0.05%, 0.25%; dose ranging study

Conditions: Psoriasis

Summary: the objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (bsa). * have a combined total lesion severity score (tlss) of ≥ 7 for the target lesion. * have a plaque elevation score ≥ 3 of (moderate) for the target lesion. * the target lesion must have an area of at least 5 cm². * have a physicians global assessment (pga) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity. exclusion criteria: * pregnancy * current diagnosis of other types of psoriasis other than stable plaque psoriasis or has psoriasis of any kind of the face or scalp that will require active treatment during the study. * history of psoriasis that has been unresponsive to topical corticosteroid therapy. * dermatological conditions that may interfere with the clinical assessments of the signs and symptoms of psoriasis. * allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which would compromise the safety of the patient or the results of the study. * any condition that would place the study patient at undue risk by participation in the study. * radiation therapy, antineoplastic agents or immunosuppressant medication within 4 weeks prior to the first dose of study drug. * treatment with any systemic or photo antipsoriatic therapy, within 8 weeks of the first dose of study drug. * treatment within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis. * systemic steroids within 4 weeks of the first dose of the study drug. the use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study. * hormonal contraceptives for less than one complete cycle prior to entering the study. * topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study. * receipt of any drug as part of a research study within 30 days prior to first dosing.

Keywords: psoriasis topical corticosteroids plaque psoriasis
genetic variates of response to cisplatin, vinblastine, and temozolomide (cvt) in patients with metastatic melanoma

Conditions: Melanoma; Skin Cancer

Summary: the investigators want to learn to predict which tumors will respond to cvt chemotherapy. cvt is a combination of three drugs - cisplatin, vinblastine, and temozolomide. we and other investigators have used cvt in melanoma patients and found that tumors got significantly smaller in 30-40% of cases. in this study, the investigators want to get a precise idea of how many patients will respond to cvt. also they want to test which genes in the tumor are turned on and which are turned off. we hope this will teach us to know in the future which tumors will respond to cvt.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histologic proof of melanoma reviewed and confirmed at mskcc * patients must have stage iv melanoma or recurrent stage iiib or iiic melanoma. patients who are potentially respectable will be eligible. * measurable disease (recist criteria). patients must have a tumor amenable to biopsy for oligonucleotide microarray analysis and for immunohistochemistry. a pre-treatment biopsy is required; a fine needle aspirate is not adequate. * no prior cytotoxic chemotherapy for melanoma. prior immunotherapy or anti-angiogenic therapy is allowed. * no other concurrent chemotherapy, immunotherapy, or radiotherapy * ecog performance status ≤ 1 * adequate organ function defined as follows: anc \>1500/mm3, platelets \>130,000/mm3, calculated creatinine clearance ≥60 ml/minute (cockcroft \& gault). * adequate cardiac function to tolerate the hydration needed for cisplatin administration. exclusion criteria: * history of cns metastases unless brain metastases have been resected or successfully treated with stereotactic radiosurgery and the patient has been free from cns recurrence for 3 months. * uveal melanoma primary * patients who have had prior anti-ctla4 monoclonal antibody treatment must have been off treatment for at least 4 months and have signs of progression of disease. * frequent vomiting or medical conditions that could interfere with oral medication intake * serious infection requiring antibiotics, or nonmalignant medical illnesses that are uncontrolled or whose control might be jeopardized by the complications of this therapy. * history of hiv infection even if on haart * immunosuppressive drugs * high dose vitamins and herbs * other on-going investigational therapy, concurrent chemotherapy, immunotherapy or radiotherapy.

Keywords: skin cancer cisplatin temozolomide vinblastine 09-017
a study of the safety, tolerance, and pharmacokinetics of oral posaconazole in immunocompromised children (p03579)

Conditions: Fungal Infections

Summary: the purpose of this dose-escalation study is to evaluate the pharmacokinetics, safety, and tolerability of oral posaconazole in immunocompromised children with neutropenia or expected neutropenia.


Eligibility criteria:
inclusion criteria: * documented or anticipated neutropenia expected to last at least 7 days and only in the following clinical situations: acute leukemia; myelodysplasia; severe aplastic anemia; autologous hematopoietic stem cell transplantation (hsct) recipients; high risk neuroblastoma; advanced stage non-hodgkin's lymphoma; recipients of allogeneic hsct during the pre-engraftment (neutropenia) period * participants of child-bearing potential must use a medically accepted method of contraception throughout the study and for at least 30 days after stopping study medication, unless they are surgically or medically sterile or agree to remain abstinent. exclusion criteria: * proven invasive fungal infection (ifi) before study entry * severe nausea and/or vomiting at screening * received posaconazole within 10 days before screening * unable to receive study drug by mouth or via an intestinal (enteral) tube * females who are pregnant, intend to become pregnant during the study, or are breastfeeding * history of anaphylaxis attributed to the azole class of antifungal agents
transluminal attenuation gradient versus ct fractional flow reserve

Conditions: Coronary Artery Disease

Summary: coronary computed tomographic angiography (ccta) has emerged as a non-invasive test, accurately evaluate anatomic coronary artery stenosis. however, anatomically-obstructive coronary stenosis by ccta demonstrates an unreliable relationship to lesion-specific ischemia. recently, with the advance of imaging reconstruction and analysis technique, several novel parameters computed from ccta were suggested to have added value in determining the ischemia-causing coronary stenosis. in this study, diagnostic performance of transluminal attenuation gradient (tag) and fractional flow reserve computed form ccta (ffr-ccta) for the presence of hemodynamically-significant coronary stenosis, as determined by fractional flow reserve (ffr).

angiographically obtained fractional flow reserve (ffr) is a useful physiologic test for assessment of lesion-specific ischemia, and a valuable adjunct to anatomic assessment of coronary artery disease (cad) as determined by invasive coronary angiography. however, the invasiveness and measuring difficulty of ffr make it unfamiliar to perform. coronary computed tomographic angiography (ccta) has emerged as a non-invasive test, accurately evaluate anatomic coronary artery stenosis. although ccta evaluation of cad has been validated against invasive coronary angiography and intravascular ultrasound, anatomically-obstructive coronary stenosis by ccta demonstrates an unreliable relationship to lesion-specific ischemia. recently, with the advance of imaging reconstruction and analysis technique, several novel parameters computed from ccta were suggested to have added value in determining the ischemia-causing coronary stenosis. in this study, diagnostic performance of transluminal attenuation gradient (tag) and fractional flow reserve computed form ccta (ffr-ccta) for the presence of hemodynamically-significant coronary stenosis, as determined by ffr, will be compared to suggest best functional parameter noninvasively computed form ccta.

Eligibility criteria:
inclusion criteria: * age \>= 18 years old * ccta with \>=50% stenosis in a major coronary artery (\>=2.0 mm diameter) * underwent invasive coronary angiography with ffr measurement exclusion criteria: * with ccta of poor image quality

Keywords: coronary artery disease ct